Search

everythinglearnresearchcommunity

for

Search:↓

The user switched from finasteride to dutasteride while continuing minoxidil, noting thicker and faster hair growth with minimal side effects. Other users discussed transitioning between these treatments, with some experiencing side effects like gynecomastia and erectile dysfunction.

The conversation is about hair loss treatments, specifically using Dutasteride and Minoxidil since November 2025, with positive progress reported. Users discuss the effectiveness and side effects of topical and oral Minoxidil and Finasteride, with some preferring topical solutions to avoid side effects.

The user has been using Minoxidil and finasteride with success and is now trying Dualgen-5R with retinoic acid but without finasteride, along with microneedling. They plan to share results in 5-6 months.

A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

The user has been using dutasteride, RU58841, and minoxidil for hair loss, experiencing some side effects and mixed results, with RU58841 notably reducing scalp itch. Despite extensive treatment, the user has maintained hair but struggles with hairline thickening.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

The conversation discusses a hair loss treatment regimen including oral dutasteride, oral minoxidil, tadalafil, and the recent addition of RU58841. The user shares experiences with these treatments, noting significant hair regrowth and stabilization, and discusses the cost and preparation of RU58841.

A user shared their four-year experience using 0.5mg dutasteride and topical minoxidil once daily for aggressive early hair loss, maintaining their hairline and regrowing hair on the vertex. They've experienced positive social feedback and increased confidence but also deal with dry eyes from dutasteride and worry about its long-term effects and cost.

User shared 3-week progress using Pyrilutamide once a day for hair loss. Another user shared their 3-month progress with 0.25% concentration Pyrilutamide, experiencing rollback of 4 years in 3 months.

The user has been using a regimen of dutasteride (DUT) and topical minoxidil (1ml once a day) for six months, resulting in hair regrowth and increased thickness. The user reports no side effects and mentions that the shedding phase lasted about a month.

A user reports hair regrowth and thickening after 3.5 months using oral dutasteride (0.5mg) and oral minoxidil (5mg). They express gratitude for the information received from the community about hair loss treatments.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

Probiotics like L. reuteri ATCC PTA 6475 and B. longum BB536 may improve hair growth and density by reducing inflammation and reversing DHT damage. The user is trialing these probiotics personally, ordering them from the U.S. to Canada, and plans to continue if no adverse effects occur.

The user has been using finasteride inconsistently for 2 years and minoxidil for 6 months without seeing hair growth. They are considering switching to dutasteride and restarting minoxidil to address thinning at the right temple, with advice suggesting consistent use for better results.

A 28-year-old male shared progress pictures showing temple hair growth after using 5mg Minoxidil and 0.5mg Dutasteride since January 1st. Users discussed the effectiveness of these treatments, with some noting increased facial hair growth and others inquiring about the method of application.

A user shared a new hair loss treatment protocol including topical dutasteride, latanoprost, caffeine, minoxidil, tretinoin, and triamcinolone acetonide. Others discussed the effectiveness and availability of these treatments, with some suggesting simpler oral alternatives.

User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

Dutasteride can be obtained through Amazon for $13.60 a month with Prime, and some users prefer it over finasteride due to its effectiveness and similar side effects. Finasteride is also available for $16 for a 3-month supply, and some users report no side effects, while others experience issues like tenderness and swelling.

The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The user must stop minoxidil due to a heart murmur and is considering alternatives like nanoxidil or stemoxydine while continuing dutasteride. Suggestions include adding pyrilutamide and alfatradiol or switching to topical minoxidil at a lower concentration.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

The user is seeking a quicker-drying carrier for RU58841 and Minoxidil to improve adherence to their hair loss treatment routine. They want to apply it after a morning shower without affecting their hair's appearance.

OP asked if a product from Amazon is sufficient to dilute finasteride. A user advised against using propylene glycol alone, suggesting a pre-made solution instead.

The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.

RU58841's legitimacy and sourcing concerns. Users suggest caution and recommend trusted sources over platforms like Amazon.